martes, 26 de septiembre de 2023

Pharmacotherapy and pulmonary fibrosis risk after SARS-CoV-2 infection: a prospective nationwide cohort study in the United States

https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(23)00140-0/fulltext?dgcid=hubspot_update_feature_updatealerts_lanam&utm_campaign=update-lanam&utm_medium=email&_hsmi=275662992&_hsenc=p2ANqtz--k4yHiZLOc1ENyUU7i6iuJSw-xu6vvoIsnfetd27e8pT6TftAry4z6fL3HI0GxVpnPt8BsxktucS0Vy_8_XY8AhyxcTg&utm_content=275650399&utm_source=hs_email

No hay comentarios:

Publicar un comentario